PPBV News Today: Stay Updated with the Latest Purple Beverage Company, Inc. News in Real Time
Find PPBV news now at Meyka AI. Stay informed with the latest{" "} Purple Beverage Company, Inc. stocks updates, including price news, market analysis, and expert insights.
Barbeques Galore Liquidates 62 Stores, 500 Jobs Lost on June 10
Barbeques Galore enters liquidation with 62 stores closing and 500 jobs lost after rescue deal collapsed.
Hardwyn India Announces 2:5 Bonus Share Issue, June 10
Hardwyn India proposes 2:5 bonus share issue. Shareholders receive 2 bonus shares per 5 held. Stock rises 0.65% to ₹24.59. Approval vote July 3, 2026.
MTR Launches Data-Driven Precision Marketing Platform, June 10
MTR advertising launches “25 Personas” precision targeting platform across Hong Kong’s 63 metro stations, moving from mass coverage to data-driven…
OpenAI Files Confidential IPO as AI Giants Race to Public Markets, June 10
OpenAI files confidential S-1 with SEC for IPO, valued at $852 billion. Timing undecided as company joins mega-IPO wave.
TSX Composite Retreats as Rate Fears Weigh on Materials, June 09
TSX Composite retreats from record highs as employment data sparks rate concerns. Materials sector falls; AI stocks show mixed performance.
Elon Musk Nears $1 Trillion Net Worth as SpaceX IPO Launches June 12
Elon Musk’s net worth approaches $1 trillion as SpaceX IPO launches June 12 with $1.8T valuation and combined stakes exceeding $1.1 trillion.
Germany and France End €100B Fighter Jet Project, June 09
Germany and France cancel €100 billion FCAS fighter jet project after Airbus-Dassault leadership disputes. Combat Cloud may continue separately.
TELUS Stock Falls 0.8% as Dividend Yield Attracts Income Investors, June 09
TELUS stock at C$17.04 offers 9.8% dividend yield with C$20.27 analyst target. Meyka rates B- citing high debt concerns.
Parabilis Medicines Targets Up to $2.3 Billion Valuation in Expanded U.S. IPO Amid Biotech Market Rally
Parabilis Medicines is aiming for a valuation of nearly $2.3 billion through an expanded U.S. initial public offering, highlighting renewed investor confidence in the biotechnology sector. The Cambridge, Massachusetts-based company increased the size of its offering as demand for biotech IPOs continues to improve following a challenging period for the industry. The company now plans…